Summary not available.
Summary not available.
EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics have completed a merger, making EOM shareholders the majority owners of the combined entity. The merger aims to advance EOM's pipeline, focusing on immunomodulatory agents and retinal disease therapies. The new company will be known as EOM Pharmaceuticals Holdings, Inc., while the existing common stock will continue to trade under the ticker symbol IMUC until a new symbol is assigned. EOM613 and EOM147 are the key pipeline assets targeting severe COVID-19 and retinal diseases respectively.
ImmunoCellular Therapeutics (OTC: IMUC) announced compliance steps for the amended Rule 15c2-11 of the Securities and Exchange Act, effective September 2021. The company has submitted an application to the OTC and intends to submit unaudited financial statements by the compliance deadline of June 30, 2021. Non-compliance would result in loss of public trading eligibility for its common stock. This proactive measure aims to ensure transparency and maintain investor confidence ahead of the regulatory changes.